B.r.a.h.m.s Gmbh

Leong Loke Ng

Andreas Bergmann

Joachim Struck

Nils G Morgenthaler

Jana Papassotiriou

Oliver Hartmann

The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.

In vitro method for early or differential diagnosis or prognosis of myocardial infarction in a patient

The invention relates to methods for in vitro diagnosis of acute coronary syndrome (ACS), acute myocardial infarction (AMI) or angina pectoris (AP) by determining the level of neurophysin II in a sample from a patient.

Diagnosis of acute coronary syndrome, myocardial infarction, or angina pectoris by means of neurophysin II

The present invention relates to a method for the stratification of a subject having an acute or a chronic disease, wherein the disease affects endothelial function/dysfunction, comprising the steps of (i) taking a sample of bodily fluid from the subject; (ii) determining in the sample of bodily fluid the concentration of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues; (iii) stratifying the subjects into either of the categories: (a) responder to a medication for treatment of the disease, (b) non-responder to a medication for treatment of the disease not showing an unfavorable effect after having received the medication; (c) subjects showing an unfavorable effect after having received the medication. The invention also relates to the use of an antibody or a functional fragment thereof in the method according to the invention.

Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction

The invention provides methods for the diagnosis and risk stratification of adverse events in post-myocardial infarction patients by means of proADM, whereby a determination of the marker pro-adrenomedullin or partial sequence or a fragment thereof or contained in a marker combination (panel, cluster) is carried out on a post-myocardial infarction patient. The invention also provides a diagnostic device and a kit for the performance of the method of the method of the invention.

Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin

The invention relates to a method for diagnosis and/or risk classification for acute coronary syndrome (ACS), in particular for acute myocardial infarct (AMI) and angina pectoris (AP) and/or a post-myocardial infarct, wherein a determination of the C-terminal pro-endothelin (CT-proET-) or fragments and partial peptides therefrom, is carried out in combination with NT-proBNP.

Growing community of inventors

Leicester, United Kingdom

Leong Loke Ng